510(k) Report

510(k) · Cleared

Cleared

CareStart Flu A&B Plus

K191514510(k) Dual TrackCleared Feb 18, 2020256-day reviewClass II21 CFR 866.3328

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Access Bio, Inc. · PSZ Devices Detecting Influenza A, B, And C Virus Antigens

Cleared on Feb 18, 2020 as substantially equivalent to K180438 (Bd, 2018) after a 256-day review. Its family tree reaches back 13 generations to 1990. 1 later device descends from it.

Decided
Feb 18, 2020
Review
256 days
Class
Class II
Product code
PSZ
Recalls
None
Predicates
1

Its longest line of descent runs back 13 generations to K902609 (1990). 15 ancestors in all. 1 later device descends from it, 1 citing it directly.

  1. Root · 13 generations backK902609 Directigen Flu aBd Becton Dickinson Vacutainer Systems Preanalytic · 1990
  2. 9 generations between
  3. 3 generations backK152870 BD Veritor System for the Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson and Co. · 2015
  4. 2 generations backK160161 BD Veritor System for Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson & CO · 2016
  5. 1 generation backK180438 BD Veritor System for Rapid Detection of Flu A + B CLIA waived kitBd · 2018 · Recalled
  6. This deviceK191514 CareStart Flu A&B PlusAccess Bio, Inc. · 2020
  7. Descendant · cites it directly · 0 of its ownK250398 Innovita Flu A/B Antigen Rapid TestInnovita (Tangshan) Biological Technology Co., Ltd. · 2025
Show all 13 generations
  1. Root · 13 generations backK902609 Directigen Flu aBd Becton Dickinson Vacutainer Systems Preanalytic · 1990
  2. 12 generations backK981651 AB Flu OiaBiostar, Inc. · 1998
  3. 11 generations backK023556 Flu Oia a/B Test KitThermo Biostar, Inc. · 2003 · Recalled
  4. 10 generations backK031899 Quickvue Influenza a+B TestQuidel Corp. · 2003
  5. 9 generations backK053146 Quickvue Influenza a + B TestQuidel Corp. · 2005
  6. 8 generations backK092698 Quickvue Influenza a+B TestQuidel Corp. · 2009
  7. 7 generations backK112277 BD Veritor (TM) System for Rapid Detection of Flu a+BBecton, Dickinson and Company · 2011 · Recalled
  8. 6 generations backK132259 BD Veritor System for the Rapid Detection of Flu a+BBecton, Dickinson and Company · 2013
  9. 5 generations backK132692 BD Veritor System for the Rapid Detection of Flu a+BBecton, Dickinson and Company · 2013
  10. 4 generations backK151291 BD Veritor (TM) System for the Rapid Detection of Flu A+BBecton, Dickinson and Company · 2015
  11. 3 generations backK152870 BD Veritor System for the Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson and Co. · 2015
  12. 2 generations backK160161 BD Veritor System for Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson & CO · 2016
  13. 1 generation backK180438 BD Veritor System for Rapid Detection of Flu A + B CLIA waived kitBd · 2018 · Recalled
  14. This deviceK191514 CareStart Flu A&B PlusAccess Bio, Inc. · 2020

Most influential descendants

Showing 1 of 1 · See all
  • K250398Innovita Flu A/B Antigen Rapid TestInnovita (Tangshan) Biological Technology Co., Ltd. · 2025 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−13K902609Directigen Flu aBd Becton Dickinson Vacutainer Systems Preanalytic1990—
−12K981651AB Flu OiaBiostar, Inc.1998—
−11K023556Flu Oia a/B Test KitThermo Biostar, Inc.20031
−10K031899Quickvue Influenza a+B TestQuidel Corp.2003—
−9K053146Quickvue Influenza a + B TestQuidel Corp.2005—
−8K092698Quickvue Influenza a+B TestQuidel Corp.2009—
−7K112277BD Veritor (TM) System for Rapid Detection of Flu a+BBecton, Dickinson and Company20111
−6K132259BD Veritor System for the Rapid Detection of Flu a+BBecton, Dickinson and Company2013—
−5K132692BD Veritor System for the Rapid Detection of Flu a+BBecton, Dickinson and Company2013—
−4K151291BD Veritor (TM) System for the Rapid Detection of Flu A+BBecton, Dickinson and Company2015—
−3K152870BD Veritor System for the Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson and Co.2015—
−2K160161BD Veritor System for Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson & CO2016—
−1K180438BD Veritor System for Rapid Detection of Flu A + B CLIA waived kitBd20182
0 (this device)K191514CareStart Flu A&B PlusAccess Bio, Inc.2020—
+1K250398Innovita Flu A/B Antigen Rapid TestInnovita (Tangshan) Biological Technology Co., Ltd.2025—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199910
200010

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202510
FIG. 1 — Lineage of K191514, 1990–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PSZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PSZ device

  1. #1 K252283 Nano-Check Influenza A+B Testscore 14.9 · 15 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K180438BD Veritor System for Rapid Detection of Flu A + B CLIA waived kit
Summary page 4
…for Rapid Detection of Flu A - Device Name: + B CLIA waived Kit - 510(k) Number: K180438 - Manufacturer: Becton, Dickinson and Company CareStart™ Flu A&B Plus -…
Bd20182

Also cleared against K180438: 1 other device →

What descends from it? (1)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K250398Innovita Flu A/B Antigen Rapid TestInnovita (Tangshan) Biological Technology Co., Ltd.20250

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 30 years and passes through 9 companies; a new generation was cleared every 1.9 years on median.
  • 3 of the 15 ancestors have a recall of any class.
  • Of its descendants, K250398 (Innovita (Tangshan) Biological Technology Co., Ltd., 2025) has gone furthest, with 0 descendants of its own.
  • 1 other device also cites its predicate K180438.

How does its category compare?

All PSZ devices

PSZ Devices Detecting Influenza A, B, And C Virus Antigens: FDA decisions, review times, recalls and adverse event reports over 20 years. 2020, this device’s year, is highlighted.

FDA decisions per year · PSZ

2in 2025

2007: 22008: 12009: 72010: 52011: 32012: 22013: 82014: 12015: 42016: 32017: 32018: 52020: 22023: 22025: 22026 (partial year): 2
2007high 8 (2013) · low 0 (2019)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PSZ

28in 2018

2009: 20 days median2010: 29 days median2011: 80 days median2013: 28 days median2015: 27 days median2016: 29 days median2017: 200 days median2018: 28 days median
2007high 200 (2017) · low 20 (2009)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · PSZ

1in 2022

2020: 12022: 1
2007high 1 (2020) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · PSZ

60in 2025

2018: 12019: 12020: 52021: 422022: 102023: 122024: 162025: 60
2007high 60 (2025) · low 0 (2007)2025

MAUDE reports naming product code PSZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20081—00
200972000
201052900
201138000
20122—00
201382800
20141—00
201542700
201632900
2017320000
201852801
20190—01
20202—15
20210—042
20220—110
20232—012
20240—016
20252—060
20262—0—

What is it indicated for?

The CareStart™ Flu A&B Plus is an in vitro rapid immunochromatographic assay for the qualitative detection of influenza virus type A and B nucleoprotein antigens directly from nasopharyngeal swab specimens of symptomatic patients. The test is intended for use as an aid in the rapid differential diagnosis of acute influenza type A and B viral infections. This test is intended to distinguish between influenza type A and/or B virus in a single test. This…

Read the full statement (234 words)

The CareStart™ Flu A&B Plus is an in vitro rapid immunochromatographic assay for the qualitative detection of influenza virus type A and B nucleoprotein antigens directly from nasopharyngeal swab specimens of symptomatic patients.

The test is intended for use as an aid in the rapid differential diagnosis of acute influenza type A and B viral infections. This test is intended to distinguish between influenza type A and/or B virus in a single test. This test is not intended to detect influenza type C viral antigens. Negative test results are presumptive and should be confirmed by viral culture or an FDA-cleared influenza A and B molecular assay. Negative results do not preclude influenza virus infections and should not be used as the basis for treatment or other patient management decisions.

Performance characteristics for influenza A and B were established during the 2018-2019 influenza season when influenza A/H3N2, A/H1N1pdm09, and B/Victoria were the predominant influenza viruses in circulation. When other influenza viruses are emerging, performance characteristics may vary.

If infection with a novel influenza virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to the state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to received and culture specimens.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K191514: CareStart Flu A&B Plus.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K191514

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026